KalVista

KALV

ATLANTA, GA – – (ACCESSWIRE – October 6, 2022) – – Holzer & Holzer, LLC is investigating whether KalVista Pharmaceuticals, Inc.  (“KalVista” or the “Company”) (NASDAQ: KALV) complied with federal securities laws.  On October 4, 2022, the Company announced it had terminated its KOMPLETE phase 2 clinical trial for KVD824 due to the observation of liver enzyme elevations in all trial treatment groups. After this announcement, the Company’s stock price dropped.

 

If you purchased KalVista stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at  cholzer@holzerlaw.com  or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at https://holzerlaw.com/case/kalvista/ to discuss your legal rights.

Registration Deadline

Lead Plaintiff Deadline Has Passed

Submit Your Information

Name(Required)
Address
MM slash DD slash YYYY
Shares Purchased(Required)
Number of Shares Acquired
Acquisition Price Per Share
 
MM slash DD slash YYYY
Shares Sold
Number of Shares Sold
Selling Price Per Share
 
By clicking on the button below, I am requesting Holzer & Holzer, LLC send me documents necessary to retain the firm.